Navigation Links
Taconic's Litigation Contesting License Termination By Cellectis Is Dismissed
Date:7/6/2010

PARIS, July 6 /PRNewswire-FirstCall/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, announced today that the Paris Tribunal de Grande Instance has dismissed the claims filed by Taconic Artemis and Taconic Farms Inc in December 2008 against Cellectis' termination for breach of its license to homologous recombination patents.

The third chamber of the Tribunal de Grande Instance decided on Tuesday, June 29, that the agreement under which Cellectis had granted Taconic a sublicense to the patents (WO 90/11354) relating to certain uses of homologous recombination to perform targeted modifications in the genomic DNA of eukaryotic cells was legitimately terminated on August 6, 2008, for breach of the contractual terms by Taconic.

Consequently since August 6, 2008, the plaintiffs, Taconic and Taconic Artemis, have had no right under said patents to create and sell transgenic animal models. Furthermore, this decision confirms that the products sold by Taconic, namely transgenic animals constructed using the teaching of the patents, could not and still cannot be bred by a third party.

The Court recognized that Cellectis had suffered losses and damages, for which Cellectis will receive financial compensation.

An extract of the Tribunal de Grande Instance judgment is available on Cellectis' website http://www.cellectis.com/en/news-events/.

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases.  These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over 70 million euro in funding since inception.

More information at www.cellectis.com

Follow us on Twitter: twitter.com/cellectis

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
2. The Medical College of Wisconsin Adopts Quantros Event Manager(TM) and Claims Manager(TM) for Comprehensive Malpractice Litigation Management
3. Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation
4. Endocare and Galil Medical Announce Settlement of Litigation
5. OmniComm Systems Announces Settlement of Patent Litigation With DataSci, LLC
6. Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge
7. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
8. Occlutech Obtains Favourable Court Ruling in Patent Litigation in The Hague Against AGA Medical
9. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
10. AMERIGROUP Reaches Agreement in Principle to Settle Illinois Qui Tam Litigation
11. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... (PRWEB) , ... February 04, ... ... conference presented by Bloomsburg University’s Digital Forensics Club, takes place February 5-6 ... two-day event features 20+ speakers and activities such as workshops and competitions ...
(Date:2/4/2016)... February 4, 2016 --> ... acceleration company is pleased to provide the following update on ... Over the last 3 months we have significantly increased ... agreements exceeding $1,000,000. As a result, we have positioned ourselves ... Inc. license agreement and expect that development to continue on ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... supplier of Semantic Graph Database technology has been recognized As “ Best in ... Corporate America Magazine. , “At Corporate America, it’s our priority to showcase prominent ...
(Date:2/3/2016)...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), ... surfactant therapies for respiratory diseases, today announced that ... award as a component of employment compensation for ... and Chief Executive Officer.  The award was approved ... 2016 and granted as an inducement material to ...
Breaking Biology Technology:
(Date:1/28/2016)... SYNA ), a leading developer of human interface solutions, today ... --> --> Net revenue ... to the comparable quarter last year to $470.5 million. Net income ... $0.93 per diluted share. --> ... 2016 grew 9 percent over the prior year period to $60.3 ...
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/20/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce the attainment of record-setting corporate ... of the company,s laser focus on (and growing international ... comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... growth achievements in 2015 include: , Record ...
Breaking Biology News(10 mins):